Hunter Shain

Hunter Shain

@shainlab.bsky.social

UCSF, Department of Dermatology. Part of HTAN. Cancer, genomics, melanoma, cutaneous squamous cell carcinoma, dermatology, somatic mutations, tumor evolution, spatial transcriptomics, single-cell

535 followers346 following274 posts

Pinned

Clippers get the harshest punishment for a team in NBA history. Kawhi Leonard's uncle get banned from the NBA. Meanwhile Kawhi Leonard is not suspended and he keeps 20 million in laundered money? How does this dude get off scot-free?

Why can't water-intensive agriculture be moved to places with water? Grow the alfalfa in Texas and ship it cattle in the Colorado river basin. Every other natural resource has figured out how to distribute itself through supply chains.

My recommendation to CSR... If a grant mechanism has a single digit success rate, allow the applicants to submit Human Subjects and Vertebrate Animals with their JIT documents instead of with the full application.

I’m noticing an uptick in desperate emails seeking volunteer labor from faculty. It feels like a symptom of the soft-money system reaching its breaking point. What’s striking is how often list-wide requests for unpaid faculty effort go out before remuneration is even considered.

The regulatory burden for awards with a less than 10% success rate is a pure waste. Initial submissions should just be aims and research strategy. Invite discussed applications to submit all the other stuff in a 2 week window after learning that they will be discussed.

I am being asked to review a lot of papers/grants on topics where I have not published yet, but I do have active research. My theory is that AI is recommending me to editors. If correct, it is creepy that it seems to know so much about our behind-the-scenes work

I was just asked to review. The mail came from a "no-reply@" address. The only way to decline was to create a 2-factor login, fill in a dozen required fields, and navigate through a user portal. If this was a predatory, no-name entity, I would ignore it, but this was a serious request

Celeste Eggermont, Amanda Bas-Cristóbal Menéndez, Tamar Nijsten, Harmen van de Werken, Antien Mooyaart, Domenico Bellomo, Marlies Wakkee & Loes Hollestein. Funding from NIH, #HTAN, SkylineDx, and Health∼Holland, Top Sector Life Sciences & Health

Importantly, SCCore-GEP performed well on biopsy material. That creates the possibility of estimating metastatic risk before definitive excision—when the result could help guide surgical planning, imaging, follow-up and consideration of (neo)adjuvant therapy.

Gene expression told an especially clear story. Tumors formed differentiated, basal-like and mesenchymal-like groups with progressively worse metastasis-free survival. Differentiation state—not immune programs—was the dominant axis separating outcomes.

We distilled these transcriptional programs into SCCore-GEP: a 23-gene signature that largely measures tumor differentiation, with additional contributions from normal epithelial, stromal and immune cells.

We identified 38 driver genes converging on a core set of pathways. This was NOT easy because of the high mutation burden in these tumors. This is IMHO the cleanest and most curated list of driver genes in this cancer subtype to date

A key strength of this study is that we have outcome information on each tumor. Poor outcome was associated with alterations in SWI/SNF, RAS–MAPK/PI3K and TGF-β pathways, as well as several arm-level copy-number changes. These features reveal genetic routes to metastatic competence.

We started by assembling the D-SQUAME study: a nationwide Dutch cohort of 19,120 patients with detailed clinicopathologic annotation and long-term outcomes. From these, we profiled 378 tumors by RNA-seq and 147 by whole-exome sequencing, balancing tumors that did and did not metastasize.

The mutational landscape was dominated by UV radiation, with additional contributions from aging, APOBEC activity and—in immunosuppressed patients—azathioprine exposure.

cSCC is extraordinarily common with an absolute mortality on par with melanoma, yet cSCC was omitted from TCGA and is excluded from many cancer registries. We need better biology and better ways to identify high-risk tumors.

At my institution, if you are a day late taking an online training module, there is no courtesy warning -- just an email straight to your boss (for me, Dept. Chair).

And then I got to meet him in person at several meetings. The jet lag from Australia could never keep him down. He was so energetic and full of great ideas. His contributions to the field of melanoma research, and his aggressive tactics...

to combat his own glioblastoma have taught us so much. He has done incredible work to help cement the paradigm of neoadjuvant treatment, especially in cancers where this was not even on the radar. Richard will be dearly missed.

I remember drafting, editing, and redrafting emails to him (before AI helped with this kind of stuff) because I was so nervous as a trainee to reach out for help, and he would reply instantaneously with enthusiasm "Sure!" to whatever I asked.

Hunter Shain reposted

Celebrating 4 oral presentations from our team at the Society of Investigative Dermatology Meeting in Chicago! Loes Hollestein @sharmaharsh.bsky.social Bárbara Rentroia Pacheco and myself with support from Arne Van Hoeck and Domenico Bellomo of SkylineDx BV. Look out for new prognostic tests in cSCC

View full thread

They localize to different areas within the biopsy. The copy number calls can distinguish individual tumor cells from normal cells and from different subclones

Excited to share that our paper, “Somatic mutations distinguish melanocyte subpopulations in human skin,” is now out in Nature Cell Biology. Reposting the thread below ⬇️